Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAL0921 in healthy subjects
NCT05891366Phase 1Completed
- Sponsor
- Walden Biosciences, Inc.
- Start
- May 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic kidney disease (CKD) and glomerular disease comparing WAL0921 with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events. Started May 2023; status: completed.
02
Drugs
WAL0921
03
Conditions
chronic kidney disease (CKD)glomerular disease
Beyond the preview
Go deeper on NCT05891366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891366.